The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease

Karuppagounder, Senthilkumar S., Brahmachari, Saurav, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M., Ko, Han Seok·2014·Scientific Reports
DOI 10.1038/srep04874

Cited by (268)

Items 101–200 of 268

  1. Mitochondrial Aging in the CNS: Unravelling Implications for Neurological Health and Disease
    Davide Steffan, Camilla Pezzini, Martina Esposito, Anaïs Franco‐Romero · 2025 · Biomolecules
  2. Autophagy and lysosomal pathways in nervous system disorders
    Baris Bingol · 2018 · Molecular and Cellular Neuroscience
  3. Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices
    Annette Dorothea Rieg, Nina A. Bünting, Christian Cranen, Said Suleiman, Jan Wilhelm Spillner, Heike Schnöring, Thomas Schröder, Saskia Freifrau von Stillfried, Till A. Braunschweig, Paul William Manley et al. · 2019 · Respiratory Research
  4. Teaching the basics of repurposing mitochondria-targeted drugs: From Parkinson's disease to cancer and back to Parkinson's disease
    Balaraman Kalyanaraman · 2020 · Redox Biology
  5. Matrix effects in nilotinib formulations with pH-responsive polymer produced by carbon dioxide-mediated precipitation
    Stefano Colombo, Magnus Brisander, Jakob Haglöf, Peter Sjövall, Per Andersson, Jesper Østergaard, Martin Malmsten · 2015 · International Journal of Pharmaceutics
  6. Therapies to Slow, Stop, or Reverse Parkinson’s Disease
    Thomas Foltynie, J. William Langston · 2018 · Journal of Parkinson s Disease
  7. Poloxamer 188 rescues MPTP‐induced lysosomal membrane integrity impairment in cellular and mouse models of Parkinson's disease
    Hongli Dong, Yuanyuan Qin, Yuyu Huang, Dongliang Ji, Feng Wu · 2019 · Neurochemistry International
  8. Genetic causes of PD: A pathway to disease modification
    Marco Toffoli, Sophia R.L. Vieira, Anthony H.V. Schapira · 2020 · Neuropharmacology
  9. Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
    Simon Stott, Richard K H Wyse, Patrik Brundin · 2021 · Frontiers in Neuroscience
  10. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration
    Hyojung Kim, Jeong‐Yong Shin, Areum Jo, Ji-Hun Kim, Sangwook Park, Jeong‐Yun Choi, Ho Chul Kang, Valina Lynn Dawson, Ted M. Dawson, Joo‐Ho Shin et al. · 2021 · Brain
  11. Indoor VOCs exposure induced Parkinson-like behaviors through autophagy dysfunction and NLRP3 inflammasome-mediated neuroinflammation
    Jie Zheng, Yaxian Pang, Yaling Zhang, Wentao Hu, Peihao Yang, Qingping Liu, Jie Ning, Zhe Du, Xiaoting Jin, Jinglong Tang et al. · 2022 · Journal of Hazardous Materials
  12. Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization
    Héctor Hernández‐Parra, Hernán Cortés, José Arturo Ávalos‐Fuentes, Marí­a Luisa Del Prado-Audelo, Benjamí­n Florán, Gerardo Leyva‐Gómez, Javad Sharifi‐Rad, William Chi Shing Cho · 2022 · Journal of Nanobiotechnology
  13. Neurodegenerative Diseases: New Hopes and Perspectives
    Mohammad Aadil Bhat, Suneela Sunil Dhaneshwar · 2023 · Current Molecular Medicine
  14. In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
    Maria Fouka, Panagiota Mavroeidi, Grigoria Tsaka, Maria Xilouri · 2020 · Frontiers in Cell and Developmental Biology
  15. New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics
    S. Pablo Sardi, Tanya Simuni · 2018 · Parkinsonism & Related Disorders
  16. Atp7b-dependent choroid plexus dysfunction causes transient copper deficit and metabolic changes in the developing mouse brain
    Clorissa Washington-Hughes, Shubhrajit Roy, Herana Kamal Seneviratne, Senthilkumar S. Karuppagounder, Yulemni Morel, Jace W. Jones, Alex Zak, Tong Xiao, Tatiana N. Boronina, Robert Norman Cole et al. · 2023 · PLoS Genetics
  17. Old wines in new bottles: Repurposing opportunities for Parkinson's disease
    Ashish Kumar Kakkar, Harmanjit Singh, Bikash Medhi · 2018 · European Journal of Pharmacology
  18. Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
    Victoria Sidoroff, Pam Bower, Nadia Stefanova, Alessandra Fanciulli, Iva Stankovic, Werner H Poewe, Klaus Seppi, Gregor Karl Wenning, Florian Krismer · 2022 · Journal of Parkinson s Disease
  19. Site-specific mitochondrial dysfunction in neurodegeneration
    Anežka Vodičková, Shon A. Koren, Andrew P. Wojtovich · 2022 · Mitochondrion
  20. Nilotinib in Parkinson's disease: A systematic review and meta-analysis
    Xiaolu Xie, Ping Yuan, Liqiu Kou, Xiu Chen, Jun Li, Yaling Li · 2022 · Frontiers in Aging Neuroscience
  21. Identification and Experimental Validation of Parkinson’s Disease with Major Depressive Disorder Common Genes
    Huiqing Wang, Shanshan Dou, Chunmei Wang, Wenming Gao, Baohua Cheng, Fuling Yan · 2023 · Molecular Neurobiology
  22. A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases
    Aleksandra Baranczak, Jeffery W. Kelly · 2016 · Current Opinion in Chemical Biology
  23. The dual role of c‐src in cell‐to‐cell transmission of α‐synuclein
    Yu Ree Choi, Jae‐Bong Kim, Seo‐Jun Kang, Hye Rin Noh, Ilo Jou, Eun-hye Joe, Sang Myun Park · 2020 · EMBO Reports
  24. Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B
    Baojian Guo, Shengquan Hu, Chengyou Zheng, Hongyu Wang, Fangcheng Luo, Haitao Li, Wei Cui, Xifei Yang, Guozhen Cui, Shinghung Mak et al. · 2017 · Neuropharmacology
  25. c-Abl activates RIPK3 signaling in Gaucher disease
    Maria Jose Yañez, Fabián Campos, Tamara Marín, Andrés D. Klein, Anthony H. Futerman, Alejandra R. Alvarez, Silvana Zanlungo · 2021 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  26. Prospects for Disease Slowing in Parkinson Disease
    Elisa Menozzi, Anthony H.V. Schapira · 2024 · The Annual Review of Pharmacology and Toxicology
  27. Molecular Symphony of Mitophagy: Ubiquitin‐Specific Protease‐30 as a Maestro for Precision Management of Neurodegenerative Diseases
    Ankit Siwach, Harit Patel, Amit Khairnar, Pathik Parekh · 2025 · CNS Neuroscience & Therapeutics
  28. Protective role of anticancer drugs in neurodegenerative disorders: A drug repurposing approach
    Dia Advani, Rohan V. Gupta, Rahul S. Tripathi, Sudhanshu Sharma, Rashmi K. Ambasta, Pravir Kumar · 2020 · Neurochemistry International
  29. Precision Medicine in Parkinson’s Disease: From Genetic Risk Signals to Personalized Therapy
    Giulia Straccia, Fabiana Colucci, Roberto Eleopra, Roberto Cilia · 2022 · Brain Sciences
  30. Role of the microtubule-associated TPPP/p25 in Parkinson’s and related diseases and its therapeutic potential
    Judit Oláh, Philippe Bertrand, Judit Ovádi · 2017 · Expert Review of Proteomics
  31. Neurodegenerative diseases: model organisms, pathology and autophagy
    Shwetha Suresh, Vijaya Verma, Shruthi Sateesh, James Premdoss Clement, Ravi R. Manjithaya · 2018 · Journal of Genetics
  32. LK6/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration
    Shiqing Zhang, Jiang Xie, Ying Xia, Shu Yu, Zhi-li Gu, Ruili Feng, Guanghong Luo, Dong Wang, Kai Wang, Meng Jiang et al. · 2015 · Scientific Reports
  33. Nonreceptor Tyrosine Kinase c‐Abl‐Mediated PHB2 Phosphorylation Aggravates Mitophagy Disorder in Parkinson’s Disease Model
    Yongjiang Zhang, Jiannan Wu, Wei‐Na Jin, Mengmeng Shen, Shiyi Yin, Xiaoyi Lai, Hongxia Ma, Menghan Jiang, Dongxue Sun, Junqiang Yan · 2022 · Oxidative Medicine and Cellular Longevity
  34. A recent update on drugs and alternative approaches for parkinsonism
    Sneha Kispotta, Debajyoti Das, Shakti Ketan Prusty · 2024 · Neuropeptides
  35. KSRMF: Kernelized similarity based regularized matrix factorization framework for predicting anti-cancer drug responses
    Aman Sharma, Rinkle Rani · 2018 · Journal of Intelligent & Fuzzy Systems
  36. The c-Abl inhibitor in Parkinson disease
    Zhihua Zhou, Yunfan Wu, Xue-min Wang, Yongzhu Han · 2017 · Neurological Sciences
  37. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative
    Richard K H Wyse, Tom Isaacs, Roger A. Barker, Mark Cookson, Ted M. Dawson, David Devos, David Trevor Dexter, Joy Duffen, Howard J. Federoff, Brian K. Fiske et al. · 2024 · Journal of Parkinson s Disease
  38. Therapeutic innovation in Parkinson’s disease: a 2020 update on disease-modifying approaches
    Daniele Colombo, Paraskevi Pnevmatikou, Elsa Melloni, Charlotte Keywood · 2020 · Expert Review of Neurotherapeutics
  39. Negative Conditioning of Mitochondrial Dysfunction in Age-related Neurodegenerative Diseases.
    Sharmelee Selvaraji, Luting Poh, Venkateswaran Natarajan, Karthik Babu Mallilankaraman, Thiruma Valavan Arumugam · 2019 · PubMed
  40. Abl depletion via autophagy mediates the beneficial effects of quercetin against Alzheimer pathology across species
    Alfonso Schiavi, Claudia Cirotti, Lora‐Sophie Gerber, Giulia Di Lauro, Silvia Maglioni, Priscila Yumi Tanaka Shibao, Sabrina Montresor, Janine Kirstein, Patrick Petzsch, Karl Köhrer et al. · 2023 · Cell Death Discovery
  41. Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease
    Juanjuan Du, Shengdi Chen · 2017 · Chinese Medical Journal
  42. Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
    Viswanath Das, John Holmes Miller, Alladi Charanraj Goud, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch · 2024 · Medicinal Research Reviews
  43. High-content phenotypic screen to identify small molecule enhancers of Parkin-dependent ubiquitination and mitophagy
    Roberta Tufi, Emily H. Clark, Tamaki Hoshikawa, Christiana Tsagkaraki, Jack Stanley, Kunitoshi Takeda, James M. Staddon, Thomas Briston · 2023 · SLAS DISCOVERY
  44. Hybrids of polyphenolic/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate α-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice
    Ming-Huan Lü, Zhenping Wang, Li-Zi Xing, Wei Zhang, Feng Han, Guolong Huang, Wei Liu, Yunxiao Zhang, Jinquan Cui, Jinquan Cui · 2023 · European Journal of Medicinal Chemistry
  45. Kinase-Based Taming of Brain Microglia Toward Disease-Modifying Therapy
    Sun Hwa Lee, Kyoungho Suk · 2018 · Frontiers in Cellular Neuroscience
  46. The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model
    Tamara Marín, Cristian Valls, Carolina Jerez, Tomás Huerta, Daniela Elgueta, René L. Vidal, Alejandra R. Alvarez, Gonzalo I. Cancino · 2022 · IBRO Neuroscience Reports
  47. Novel approaches to counter protein aggregation pathology in Parkinson's disease
    Simon Stott, Richard K H Wyse, Patrik Brundin · 2019 · Progress in brain research
  48. Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson’s Disease
    Thomas M. Kaiser, Zackery W. Dentmon, Christopher E. Dalloul, Savita K. Sharma, Dennis C. Liotta · 2020 · ACS Medicinal Chemistry Letters
  49. Beneficial effects of nilotinib, tyrosine kinase inhibitor on cyclosporine-A induced renal damage in rats
    Manar A. Nader, Ghalia M. Attia · 2016 · International Immunopharmacology
  50. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy
    Miguel Lopez Cuina, Paul A. Guerin, Marie‐Hélène Canron, Anna Delamarre, Benjamin Dehay, Erwan Bézard, Wassilios G. Meissner, Pierre‐Olivier Fernagut · 2020 · Movement Disorders
  51. Clinical symptoms, underlying pathogenesis, and the prospect of tailored therapies have all benefited from genetic discoveries in Parkinson's disease
    Moataz Dowaidar · 2021
  52. Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
    Seong Ho Jeong, Phil Hyu Lee · 2025 · Journal of Movement Disorders
  53. Degradation of alpha-synuclein by dendritic cell factor 1 delays neurodegeneration and extends lifespan in Drosophila
    Shiqing Zhang, Ruili Feng, Yanhui Li, Linhua Gan, Fangfang Zhou, Shiquan Meng, Qian Li, Tieqiao Wen · 2018 · Neurobiology of Aging
  54. Recent Advances in Drug Repurposing for Parkinson’s Disease
    Xin Chen, Giuseppe Gumina, Kristopher G. Virga · 2018 · Current Medicinal Chemistry
  55. Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination
    Ahmed E. Goda, Alaa E. El‐Sisi, Samia Salem Sokar, Noha M. Abdelrazik · 2020 · Toxicology and Applied Pharmacology
  56. Glutathione Liposomes Carrying Ceftriaxone, FK506, and Nilotinib to Control Overexpressed Dopamine Markers and Apoptotic Factors in Neurons
    Yung‐Chih Kuo, He-Cheng Tsai, Rajendiran Rajesh · 2021 · ACS Biomaterials Science & Engineering
  57. A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson’s Disease
    Seung‐Hwan Kwon, Sangjune Kim, A Yeong Park, Saebom Lee, Changdev Gorakshnath Gadhe, Bo Am Seo, Jong Sung Park, Suyeon Jo, Yumin Oh, Sin Ho Kweon et al. · 2021 · Journal of Medicinal Chemistry
  58. c-Abl Phosphorylates MFN2 to Regulate Mitochondrial Morphology in Cells under Endoplasmic Reticulum and Oxidative Stress, Impacting Cell Survival and Neurodegeneration
    Alexis N. Martinez, Cristian M. Lamaizon, Cristian Valls, Fabien Llambi, Nancy R. Leal, Patrick Fitzgerald, Cliff S. Guy, Marcin M. Kamiński, Nibaldo C. Inestrosa, Brigitte van Zundert et al. · 2023 · Antioxidants
  59. Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
    Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, Ritam Bandopadhyay, Mohammed M. Ghoneim, Sultan Alshehri, Murtada Taha, Javed Ahmad, Awanish Mishra · 2023 · Metabolic Brain Disease
  60. Therapeutic potential of Parkin and its regulation in Parkinson’s disease
    Narukkottil Safreena, Indu C. Nair, Goutam Chandra · 2024 · Biochemical Pharmacology
  61. Preclinical studies and transcriptome analysis in a model of Parkinson’s disease with dopaminergic ZNF746 expression
    Ji-Hun Kim, Sumin Yang, Hyojung Kim, Dang-Khoa Vo, Han‐Joo Maeng, Areum Jo, Jooheon H. Shin, Joo‐Ho Shin, Hyeon‐Man Baek, Gum Hwa Lee et al. · 2025 · Molecular Neurodegeneration
  62. The Role of Membrane Affinity and Binding Modes in Alpha-Synuclein Regulation of Vesicle Release and Trafficking
    Tapojyoti Das, Meraj Ramezani, David Snead, Cristian Follmer, Peter J. Chung, Ka Yee Lee, David A. Holowka, Barbara A. Baird, David Eliezer · 2022 · Biomolecules
  63. c-Abl contributes to glucose-promoted apoptosis via p53 signaling pathway in podocytes
    Yiqiong Ma, Qian Yang, Xinghua Chen, Wei Liang, Zhilong Ren, Guohua Ding · 2016 · Diabetes Research and Clinical Practice
  64. Spatiotemporal analysis of soluble aggregates and autophagy markers in the R6/2 mouse model
    Manjeet Kumar, Devanshi Shah, Mridhula Giridharan, Niraj Yadav, Ravi R. Manjithaya, James Premdoss Clement · 2021 · Scientific Reports
  65. Roles for c-Abl in postoperative neurodegeneration
    Long Feng, Shihui Fu, Yao Yao, Yulong Li, Longhe Xu, Yali Zhao, Leiming Luo · 2022 · International Journal of Medical Sciences
  66. An update on novel and emerging therapeutic targets in Parkinson’s disease
    Richa Sawant, Angel Pavalu Godad · 2024 · Metabolic Brain Disease
  67. Beyond expectations: investigating nilotinib’s potential in attenuating neurodegeneration in Alzheimer’s disease
    Darcy R. Tocci, Maiah Fogel, Vanya Gupta, Peter Sang-Hui Kim, Jean J. Latimer, Aida Adlimoghaddam, Lisa S. Robison, Benedict C. Albensi · 2025 · Alzheimer s Research & Therapy
  68. A Review on Mitochondrial Dysfunction and Oxidative stress due to Complex-Ⅰ in Parkinson Disease
    Varshini Babu, Navneet Khurana · 2021 · Research Journal of Pharmacology and Pharmacodynamics
  69. Pre-clinical Aspects and Contemporary Treatments of Parkinson’s Disease
    Partosh Chhabra, Rishabh Rishabh, Shivani Singla, Sunayna Choudhary, Shivam Kohli, Nitin Bansal, Seema Bansal · 2023 · CNS & Neurological Disorders - Drug Targets
  70. Prophylactic treatment with the c-Abl inhibitor, neurotinib, diminishes neuronal damage and the convulsive state in pilocarpine-induced mice
    América Chandía-Cristi, Daniela A. Gutiérrez, Andrés E. Dulcey, Marcelo Lara, Lina Vargas, Yi-Han Lin, Pablo Jimenez-Muñoz, Gabriela Larenas, Xin Xu, Amy Y. Wang et al. · 2024 · Cell Reports
  71. Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
    Jaimin Patel, Nikhil Panicker, Valina Lynn Dawson, Ted M. Dawson · 2022 · CNS Drugs
  72. Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
    Tridente, Giuseppe, Jana, Ankit, Nath, Arnab, Ashraf, Ghulam Md · 2023 · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders
  73. Discovery of 4-methyl-3-(pyridin-2-ylamino)benzamide derivatives as C-Abl inhibitors with potential neuroprotective effect
    Zichao Yang, Yangcheng Ai, Shanhe Wan, Zilong Yang, Honghao Li, Zhonghuang Li, Chunhui Huang, Lishun Zhang, Mingxia Li, Jiajie Zhang et al. · 2022 · Bioorganic & Medicinal Chemistry
  74. Pharmacological inhibition of AIMP2 aggregation attenuates α-synuclein aggregation and toxicity in Parkinson’s disease
    Jeong‐Yong Shin, Bina Lee, Sangwoo Ham, Jihun Kim, Hyojung Kim, Heejeong Kim, Min Gi Jo, Hye Jung Kim, Sang Won Park, Hee‐Seok Kweon et al. · 2022 · Biomedicine & Pharmacotherapy
  75. Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer’s disease using multiple e-pharmacophore modeling and molecular dynamics
    Ravichand Palakurti, Ramakrishna Vadrevu · 2016 · Journal of Biomolecular Structure and Dynamics
  76. c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
    Yu Zhou, Yukio Yamamura, Masatoshi Ogawa, Ryosuke Tsuji, Koichiro Tsuchiya, Jiro Kasahara, Satoshi Goto · 2018 · Frontiers in Pharmacology
  77. Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis
    Daisuke Kodama, Masakazu Tanaka, Toshio Matsuzaki, Kimiko Izumo, Nobuaki Nakano, Eiji Matsuura, Mineki Saito, Masahiro Nagai, Masahisa Horiuchi, Atae Utsunomiya et al. · 2020 · PLoS neglected tropical diseases
  78. c‐Abl‐induced Olig2 phosphorylation regulates the proliferation of oligodendrocyte precursor cells
    Jun Zhang, Jian-guang Sun, Xiaowen Xing, Rong-Rong Wu, Lujun Zhou, Ying Zhang, Fang Yuan, Shukun Wang, Zeng-Qiang Yuan · 2022 · Glia
  79. A high-affinity cocaine binding site associated with the brain acid soluble protein 1
    Maged M. Harraz, Adarsha P. Malla, Evan R. Semenza, Maria Shishikura, Manisha Singh, Yun Hwang, In Guk Kang, Young Jun Song, Adele M. Snowman, Pedro Cortés et al. · 2022 · Proceedings of the National Academy of Sciences
  80. Defying c-Abl signaling circuits through small allosteric compounds
    Stefania Gonfloni · 2014 · Frontiers in Genetics
  81. Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Animal Models of Parkinson’s Disease
    Jiro Kasahara, Mohammed Emamussalehin Choudhury, Noriko Nishikawa, Akie Tanabe, Ryosuke Tsuji, Yu Zhou, Masatoshi Ogawa, Hironori Yokoyama, Junya Tanaka, Masahiro Nomoto · 2017 · Elsevier eBooks
  82. Etiology and pathogenesis of Parkinson disease
    Joseph J. Jankovic, Mark Hallett, Michael S. Okun, Cynthia Comella, Stanley Fahn, Jennifer G. Goldman · 2021 · Elsevier eBooks
  83. Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson’s Disease
    Sangwoo Ham, Heejeong Kim, Jin‐Ha Yoon, Hyojung Kim, Bo Reum Song, Jeong‐Yun Choi, Yun‐Song Lee, Seung‐Mann Paek, Han‐Joo Maeng, Yunjong Lee · 2019 · International Journal of Molecular Sciences
  84. Repurposing of Kinase Inhibitors to Target c-Abl as Potential Therapeutics for Alzheimer’s Disease
    Qingzhang Zhu, Jianchun Chen, Xi Lawrence Wu, Xiaoping Jin, Bing Ruan · 2014 · Journal of Pharmaceutical Innovation
  85. Evaluation of c-Abl inhibitor vodobatinib in subjects with early Parkinson’s disease: a phase 2, randomized, double-blind, placebo-controlled study
    Harini Sarva, Rajesh Pahwa, Jorge Hernández‐Vara, Mark A. Goldstein, Rupam Borgohain, Stewart Alan Factor, Sandeep Inamdar, Damon K. Love, Carrie Hames, Yiyong Fu et al. · 2026 · npj Parkinson s Disease
  86. Abelson Tyrosine Kinase Inhibitors in Parkinson's Disease and Lewy Body Dementia: A Systematic Review, Meta-analysis, and Meta-regression
    Giovanni Gosch Berton, Amanda Cyntia Lima Fonseca Rodrigues, Rafael dos Santos Borges, Nicole Rodrigues Cardoso, Thiago Abrahão de Oliveira, Marcos Vinícius Oliveira Marques · 2024 · Clinical Neuropharmacology
  87. Disease modifying therapies for Parkinson's disease: Novel targets
    Nirosen Vijiaratnam, Thomas Foltynie · 2021 · Neuropharmacology
  88. Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): Could It Be a Promising Biomarker and Therapeutic Target in Parkinson’s Disease?
    Sijia Yin, Chao Han, Yun Fei Xia, Fang Jung Wan, Junjie Hu, Liang Kou, Yadi Sun, Jiawei Wu, Yunna Li, Qiulu Zhou et al. · 2022 · Molecular Neurobiology
  89. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma
    Kirti Kandhwal Chahal, Jie Li, Irina Kufareva, Milind Parle, Donald L. Durden, Robert J. Wechsler‐Reya, Clark C. Chen, Ruben A Abagyan · 2019 · PLoS ONE
  90. Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies
    Priti Jain, Shreyans Kumar Jain, Munendra Jain · 2020 · Current Molecular Medicine
  91. Review on cerebral malaria—Pathogenesis and role of EphA2 receptor in maintaining blood brain barrier integrity
    Mohd Sayeed Shaikh, Mirza Salman Baig, Syed Sarfaraz Ali, Anas Ahmad, Mohammad Taha Mustafa Shaikh, Paresh R. Mahaparale, Md. Faiyazuddin · 2024 · Health Sciences Review
  92. Discovery of potential Leonurine-based therapeutic lead MJ210 attenuates Parkinson's disease pathogenesis via NF-κB and MAPK pathways: Mechanistic insights from in vitro and in vivo rotenone models
    Sanju Gupta, Moumita Jash, Juhee Khan, Shubham Garg, Rajsekhar Roy, Mohammad Umar Arshi, Prasunpriya Nayak, Surajit Ghosh · 2025 · European Journal of Medicinal Chemistry
  93. Pathological and clinical aspects of alpha/beta synuclein in Parkinson’s disease and related disorders
    Michael Tolmasov, Ruth Djaldetti, Nirit Lev, Yossi Gilgun‐Sherki · 2016 · Expert Review of Neurotherapeutics
  94. The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia
    Woo Jin Lee, Jangsup Moon, Tae‐Joon Kim, Jin‐Sun Jun, Han Sang Lee, Young Jin Ryu, Soon‐Tae Lee, Keun‐Hwa Jung, Kyung‐Il Park, Ki‐Young Jung et al. · 2017 · Journal of Neuroimmunology
  95. Anticancer drugs for Parkinson's disease: Is it a ray of hope or only hype?
    Vinay Goyal, Deepa Dash · 2018 · Annals of Indian Academy of Neurology
  96. An update on the monogenic causes of Parkinson’s disease: Impact on patient stratification and personalised medicine
    Sakeena Asmi, Anand Krishnan, Sneha Mary Alexander, Jimna Mohamed Ameer, T. Nidhish, Sen Chandra Sreetama, Keerthi Tr, Rajesh Anantha Shenoi, S G S Chakravarthy, Goutam Chandra · 2026 · Ageing Research Reviews
  97. Nilotinib as a Prospective Treatment for Alzheimer’s Disease: Effect on Proteins Involved in Neurodegeneration and Neuronal Homeostasis
    Ankita Srivastava, Heather A. Renna, Maryann Johnson, Katie Sheehan, Saba Ahmed, Thomas A. Palaia, Aaron Pinkhasov, Irving H. Gomolin, Thomas Wısnıewskı, Joshua De Leon et al. · 2024 · Life
  98. The Search for Disease Modification in Parkinson’s Disease—A Review of the Literature
    Daniel Barber, Tissa Wijeratne, Lakshman Singh, Kevin Jeffrey Barnham, Colin Louis Masters · 2025 · Life
  99. Development of 18F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson’s Disease
    E. Johanna L. Stéen, A Yeong Park, Wissam Beaino, Changdev Gorakshnath Gadhe, Esther J. M. Kooijman, Robert C. Schuit, Maxime Schreurs, Prisca S. Leferink, Jeroen J.M. Hoozemans, Jae Eun Kim et al. · 2023 · Journal of Medicinal Chemistry
  100. Comparative In silico evaluation of c-Abl inhibitors for Parkinson's disease therapy
    Devu B. Kumar, Santhosh Kumar Subramanya, Poonam Singh Thakur · 2025 · Biochemical and Biophysical Research Communications